 "DRDO's 2DG anti-Covid drug priced at Rs 990 per sachet: Dr Reddy's")
Dr Reddy's Laboratories on Wednesday said it has launched vasopressin injection, which is used to control frequent urination, increased thirst, and loss of water caused by diabetes, in the American market.
The company has launched the product, a generic version of Par Pharmaceuticals' Vasostrict, in the US market after getting approval from the US Food and Drug Administration (USFDA).
We are pleased to provide this important authorised generic product to patients, especially in these difficult times of COVID-19, Dr Reddy's Laboratories Inc North America Generics CEO Marc Kikuchi said in a statement.
According to IQVIA Health, Vasostrict brand had sales of around USD 878.5 million for the most recent twelve months ending December 2021.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
